MET receptor tyrosine kinase as a therapeutic anticancer target

Cancer Letters

Volumn 280, Issue 1, 2009, Pages 1-14

  Stellrecht, Christine M ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hepatocyte growth factor; Met; Receptor tyrosine kinase; Targeted therapy

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AMG 102; ANTINEOPLASTIC AGENT; ARQ 197; CE 355621; CNF 1010; CORDYCEPIN; FLAVOPIRIDOL; GELDANAMYCIN; GSK 1363089; INCBO 28060; MGCD 265; MP 470; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PF 04217903; PF 4254644; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SGX 126; SNX 5422; SU 11271; SU 11606; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 184; XL 880;

CLINICAL TRIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTO ONCOGENE; SHORT SURVEY;

EID: 67349189814     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.045     Document Type: Review

References (118)

1. Cooper C.S., Park M., Blair D.G., Tainsky M.A., Huebner K., Croce C.M., and Vande Woude G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311 (1984) 29-33
2. Blair D.G., Cooper C.S., Oskarsson M.K., Eader L.A., and Vande Woude G.F. New method for detecting cellular transforming genes. Science 218 (1982) 1122-1125
3. Comoglio P.M., and Boccaccio C. Scatter factors and invasive growth. Semin. Cancer Biol. 11 (2001) 153-165
4. Furge K.A., Zhang Y.W., and Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19 (2000) 5582-5589
5. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met metastasis motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925
6. Gentile A., Trusolino L., and Comoglio P.M. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27 (2008) 85-94
7. Christensen J.G., Burrows J., and Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225 (2005) 1-26
8. Ma P.C., Maulik G., Christensen J., and Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22 (2003) 309-325
9. Maestrini E., Tamagnone L., Longati P., Cremona O., Gulisano M., Bione S., Tamanini F., Neel B.G., Toniolo D., and Comoglio P.M. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc. Natl. Acad. Sci. USA 93 (1996) 674-678
10. Liu Y. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene 215 (1998) 159-169
11. Ikehara S. Role of hepatocyte growth factor in hemopoiesis. Leuk. Lymphoma 23 (1996) 297-303
12. van der Voort R., Taher T.E., Derksen P.W., Spaargaren M., van der Neut R., and Pals S.T. The hepatocyte growth factor/Met pathway in development tumorigenesis and B-cell differentiation. Adv. Cancer Res. 79 (2000) 39-90
13. van der Voort R., Taher T.E., Keehnen R.M., Smit L., Groenink M., and Pals S.T. Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway. J. Exp. Med. 185 (1997) 2121-2131
14. Sachs M., Weidner K.M., Brinkmann V., Walther I., Obermeier A., Ullrich A., and Birchmeier W. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J. Cell Biol. 133 (1996) 1095-1107
15. Comoglio P.M. Pathway specificity for Met signalling. Nat. Cell Biol. 3 (2001) E161-E162
16. Maroun C.R., Holgado-Madruga M., Royal I., Naujokas M.A., Fournier T.M., Wong A.J., and Park M. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 19 (1999) 1784-1799
17. Santoro M.M., Collesi C., Grisendi S., Gaudino G., and Comoglio P.M. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol. Cell. Biol. 16 (1996) 7072-7083
18. Herynk M.H., Tsan R., Radinsky R., and Gallick G.E. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin. Exp. Metastasis 20 (2003) 291-300
19. Muller M., Morotti A., and Ponzetto C. Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol. Cell. Biol. 22 (2002) 1060-1072
20. Kermorgant S., and Parker P.J. C-Met signalling: spatio-temporal decisions. Cell Cycle 4 (2005) 352-355
21. Jo M., Stolz D.B., Esplen J.E., Dorko K., Michalopoulos G.K., and Strom S.C. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J. Biol. Chem. 275 (2000) 8806-8811
22. Khoury H., Naujokas M.A., Zuo D., Sangwan V., Frigault M.M., Petkiewicz S., Dankort D.L., Muller W.J., and Park M. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol. Biol. Cell 16 (2005) 550-561
23. Reznik T.E., Sang Y., Ma Y., Abounader R., Rosen E.M., Xia S., and Laterra J. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 6 (2008) 139-150 %R 10.1158/1541-7786.MCR-07-0236
24. Maggiora P., Lorenzato A., Fracchioli S., Costa B., Castagnaro M., Arisio R., Katsaros D., Massobrio M., Comoglio P.M., and Flavia Di Renzo M. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp. Cell Res. 288 (2003) 382-389
25. Bertotti A., Comoglio P.M., and Trusolino L. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J. Cell Biol. 175 (2006) 993-1003
26. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.J., Walther M.M., Tsui L.C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L., Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S., Lerman M.I., Linehan W.M., and Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16 (1997) 68-73
27. Ma P.C., Tretiakova M.S., Mackinnon A.C., Ramnath N., Johnson C., Dietrich S., Seiwert T., Christensen J.G., Jagadeeswaran R., Krausz T., Vokes E.E., Husain A.N., and Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47 (2008) 1025-1037
28. Hartmann G., Naldini L., Weidner K.M., Sachs M., Vigna E., Comoglio P.M., and Birchmeier W. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc. Natl. Acad. Sci. USA 89 (1992) 11574-11578
29. Guerin C., Luddy C., Abounader R., Lal B., and Laterra J. An antagonist of scatter factor/hepatocyte growth factor, Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. Biochem. Biophys. Res. Commun. 273 (2000) 287-293
30. Cioce V., Csaky K.G., Chan A.M., Bottaro D.P., Taylor W.G., Jensen R., Aaronson S.A., and Rubin J.S. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J. Biol. Chem. 271 (1996) 13110-13115
31. Tolbert W.D., Daugherty J., Gao C., Xie Q., Miranti C., Gherardi E., Woude G.V., and Xu H.E. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc. Natl. Acad. Sci. USA 104 (2007) 14592-14597
32. Youles M., Holmes O., Petoukhov M.V., Nessen M.A., Stivala S., Svergun D.I., and Gherardi E. Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J. Mol. Biol. 377 (2008) 616-622
33. Date K., Matsumoto K., Shimura H., Tanaka M., and Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. 420 (1997) 1-6
34. Matsumoto K., and Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. Front. Biosci. 13 (2008) 1943-1951
35. Mazzone M., Basilico C., Cavassa S., Pennacchietti S., Risio M., Naldini L., Comoglio P.M., and Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest. 114 (2004) 1418-1432
36. Kong-Beltran M., Stamos J., and Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6 (2004) 75-84
37. Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., and Comoglio P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6 (2004) 61-73
38. Cao B., Su Y., Oskarsson M., Zhao P., Kort E.J., Fisher R.J., Wang L.M., and Vande Woude G.F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 98 (2001) 7443-7448
39. Kim K.J., Wang L., Su Y.C., Gillespie G.Y., Salhotra A., Lal B., and Laterra J. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 12 (2006) 1292-1298
40. Burgess T., Coxon A., Meyer S., Sun J., Rex K., Tsuruda T., Chen Q., Ho S.Y., Li L., Kaufman S., McDorman K., Cattley R.C., Sun J., Elliott G., Zhang K., Feng X., Jia X.C., Green L., Radinsky R., and Kendall R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66 (2006) 1721-1729
41. Jun H.T., Sun J., Rex K., Radinsky R., Kendall R., Coxon A., and Burgess T.L. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 13 (2007) 6735-6742
42. Reardon D.A., Cloughsey T.F., Raizer J.J., Laterra J., Schiff D., Yang X., Loh E., and Wen P.Y. Phase II study of AMG 102 a fully human neutralizing antibody against hepatocyte growth factor/scatter factor in patients with recurrent glioblastoma multiforme. J. Clin. Oncol. (Meeting Abstr.) 26 (2008) 2051
43. Petrelli A., Circosta P., Granziero L., Mazzone M., Pisacane A., Fenoglio S., Comoglio P.M., and Giordano S. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. USA 103 (2006) 5090-5095
44. Tseng J.R., Kang K.W., Dandekar M., Yaghoubi S., Lee J.H., Christensen J.G., Muir S., Vincent P.W., Michaud N.R., and Gambhir S.S. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J. Nucl. Med. 49 (2008) 129-134
45. Nguyen T.H., Loux N., Dagher I., Vons C., Carey K., Briand P., Hadchouel M., Franco D., Jouanneau J., Schwall R., and Weber A. Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther. 10 (2003) 840-849
46. Martens T., Schmidt N.O., Eckerich C., Fillbrandt R., Merchant M., Schwall R., Westphal M., and Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12 (2006) 6144-6152
47. Jin H., Yang R., Zheng Z., Romero M., Ross J., Bou-Reslan H., Carano R.A., Kasman I., Mai E., Young J., Zha J., Zhang Z., Ross S., Schwall R., Colbern G., and Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68 (2008) 4360-4368
48. Giles F.J., Cortes J.E., and Kantarjian H.M. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr. Mol. Med. 5 (2005) 615-623
49. Hov H., Holt R.U., Ro T.B., Fagerli U.M., Hjorth-Hansen H., Baykov V., Christensen J.G., Waage A., Sundan A., and Borset M. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin. Cancer Res. 10 (2004) 6686-6694
50. Ma P.C., Schaefer E., Christensen J.G., and Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin. Cancer Res. 11 (2005) 2312-2319
51. Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., Le P., Chen J., Wang X., Ruslim L., Blake R., Lipson K.E., Ramphal J., Do S., Cui J.J., Cherrington J.M., and Mendel D.B. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63 (2003) 7345-7355
52. Sattler M., Pride Y.B., Ma P., Gramlich J.L., Chu S.C., Quinnan L.A., Shirazian S., Liang C., Podar K., Christensen J.G., and Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 63 (2003) 5462-5469
53. Koon E.C., Ma P.C., Salgia R., Welch W.R., Christensen J.G., Berkowitz R.S., and Mok S.C. Effect of a c-Met-specific ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth motility and invasion. Int. J. Gynecol. Cancer 18 (2008) 976-984
54. Berthou S., Aebersold D.M., Schmidt L.S., Stroka D., Heigl C., Streit B., Stalder D., Gruber G., Liang C., Howlett A.R., Candinas D., Greiner R.H., Lipson K.E., and Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23 (2004) 5387-5393
55. Wang X., Le P., Liang C., Chan J., Kiewlich D., Miller T., Harris D., Sun L., Rice A., Vasile S., Blake R.A., Howlett A.R., Patel N., McMahon G., and Lipson K.E. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol. Cancer Ther. 2 (2003) 1085-1092
56. Smolen G.A., Sordella R., Muir B., Mohapatra G., Barmettler A., Archibald H., Kim W.J., Okimoto R.A., Bell D.W., Sgroi D.C., Christensen J.G., Settleman J., and Haber D.A. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. USA 103 (2006) 2316-2321
57. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.P., Nambu M.D., Los G., Bender S.L., Mroczkowski B., and Christensen J.G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67 (2007) 4408-4417
58. Zou H.Y., Li Q., Lee J.H., Burgess K., Ozeck M., Parker M., Pavlicek A., Cui J.J., Bender S., and Christensen J.G. Receptor tyrosine kinase cross talk affects tumor cell sensitivity to RTK inhibitors. Proc. Am. Assoc. Cancer Res. 49 (2008) LB-198
59. Srinivasan R., Choueiri T.K., Vaishampayan U., Rosenberg J.E., Stein M.N., Logan T., Bukowski R.M., Mueller T., Keer H.N., and Linehan W.M. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J. Clin. Oncol. 26 (2008) 5103
60. Yap T.A., Harris D., Barriuso J., Wright M., Riisnaes R., Clark J., Ledaki I., Savage R., Chen T., and De Bono J.S. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. J. Clin. Oncol. 26 (2008) 3584
61. Camacho L.H., Moulder S.L., LoRusso P.M., Blumenschein G.R., Bristow P.J., Kurzrock R., Fu S., Schlienger K., and Bergstrom D.A. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. J. Clin. Oncol. 26 (2008) 14657
62. Tolcher A., Berk G., Fine G., Choy G., Bearss D., Redkar S., and Tibes R. MP470, a potent oral Rad51 suppressor is safe and tolerable in first-in-human study. AACR Meeting Abstracts 2008 (2008) 4083
63. Maulik G., Kijima T., Ma P.C., Ghosh S.K., Lin J., Shapiro G.I., Schaefer E., Tibaldi E., Johnson B.E., and Salgia R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res. 8 (2002) 620-627
64. Webb C.P., Hose C.D., Koochekpour S., Jeffers M., Oskarsson M., Sausville E., Monks A., and Vande Woude G.F. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60 (2000) 342-349
65. Xie Q., Gao C.F., Shinomiya N., Sausville E., Hay R., Gustafson M., Shen Y., Wenkert D., and Vande Woude G.F. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 24 (2005) 3697-3707
66. Abounader R., Ranganathan S., Lal B., Fielding K., Book A., Dietz H., Burger P., and Laterra J. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. 91 (1999) 1548-1556
67. Abounader R., Montgomery R., Dietz H., and Laterra J. Design and expression of chimeric U1/ribozyme transgenes. Methods Mol. Biol. 252 (2004) 209-219
68. Stellrecht C.M., Phillip C.J., Cervantes-Gomez F., and Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 67 (2007) 9913-9920
69. Jiang W.G., Grimshaw D., Lane J., Martin T.A., Abounader R., Laterra J., and Mansel R.E. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin. Cancer Res. 7 (2001) 2555-2562
70. Herynk M.H., Stoeltzing O., Reinmuth N., Parikh N.U., Abounader R., Laterra J., Radinsky R., Ellis L.M., and Gallick G.E. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res. 63 (2003) 2990-2996
71. Kim S.J., Johnson M., Koterba K., Herynk M.H., Uehara H., and Gallick G.E. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin. Cancer Res. 9 (2003) 5161-5170
72. Jiang W.G., Grimshaw D., Martin T.A., Davies G., Parr C., Watkins G., Lane J., Abounader R., Laterra J., and Mansel R.E. Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clin. Cancer Res. 9 (2003) 4274-4281
73. Abounader R., Lal B., Luddy C., Koe G., Davidson B., Rosen E.M., and Laterra J. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16 (2002) 108-110
74. Bowers D.C., Fan S., Walter K.A., Abounader R., Williams J.A., Rosen E.M., and Laterra J. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res. 60 (2000) 4277-4283
75. Taulli R., Scuoppo C., Bersani F., Accornero P., Forni P.E., Miretti S., Grinza A., Allegra P., Schmitt-Ney M., Crepaldi T., and Ponzetto C. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res. 66 (2006) 4742-4749
76. Shinomiya N., Gao C.F., Xie Q., Gustafson M., Waters D.J., Zhang Y.W., and Vande Woude G.F. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res. 64 (2004) 7962-7970
77. Jagadeeswaran R., Ma P.C., Seiwert T.Y., Jagadeeswaran S., Zumba O., Nallasura V., Ahmed S., Filiberti R., Paganuzzi M., Puntoni R., Kratzke R.A., Gordon G.J., Sugarbaker D.J., Bueno R., Janamanchi V., Bindokas V.P., Kindler H.L., and Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66 (2006) 352-361
78. Corso S., Migliore C., Ghiso E., De Rosa G., Comoglio P.M., and Giordano S. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 27 (2008) 684-693
79. Leelawat K., Leelawat S., Tepaksorn P., Rattanasinganchan P., Leungchaweng A., Tohtong R., and Sobhon P. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J. Surg. Res. 136 (2006) 78-84
80. C.J. Phillip, C.M. Stellrecht, R. Nimmanapalli, V. Gandhi, Targeting MET transcription as a therapeutic strategy in multiple myeloma, Cancer Chemother, Pharmacol. (2008), in press, doi:10.1007/300280-008-0770-2.
81. Weinstein I.B. Addiction to oncogenes - the Achilles heal of cancer. Science 297 (2002) 63-64
82. Weinstein I.B., and Joe A. Oncogene addiction. Cancer Res. 68 (2008) 3077-3080 discussion 3080
83. Stellrecht C.M., Chen L.S., and Gandhi V. Inhibition of oncogene expression by RNA-directed agents Transcription as a Target for Cancer Therapeutics (2005), AACR Educational Book American Association for Cancer Research, Philadelphia PA pp. 338-343
84. Derheimer F.A., Chang C.W., and Ljungman M. Transcription inhibition: a potential strategy for cancer therapeutics. Eur. J Cancer 41 (2005) 2569-2576
85. Radhakrishnan S.K., and Gartel A.L. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res. 66 (2006) 3264-3270
86. Chen C.Y., and Shyu A.B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 20 (1995) 465-470
87. Moghul A., Lin L., Beedle A., Kanbour-Shakir A., DeFrances M.C., Liu Y., and Zarnegar R. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 9 (1994) 2045-2052
88. Stellrecht C.M., Krett N., Ayres M., Rosen S., and Gandhi V. 8-Chloro-cAMP serves as a prodrug for the RNA directed nucleoside analog 8-chloro-adenosine. In: Hiddemann W., Büchner T., Ritter J., Unterhalt M., and Haferlach T. (Eds). Acute Leukemia IX: Basic Research Experimental Approaches and Novel Therapies (2003), Springer-Verlag, Heidelberg, Germany 193-199
89. Stellrecht C.M., Rodriguez Jr. C.O., Ayres M., and Gandhi V. RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res. 63 (2003) 7968-7974
90. Chen L.S., and Sheppard T.L. Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C-8-modified ATP analogs. J. Biol. Chem. 279 (2004) 40405-40411
91. Kelland L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status,. Expert Opin. Investig. Drugs 9 (2000) 2903-2911
92. Chao S.H., Fujinaga K., Marion J.E., Taube R., Sausville E.A., Senderowicz A.M., Peterlin B.M., and Price D.H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275 (2000) 28345-28348
93. Chao S.H., and Price D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276 (2001) 31793-31799
94. Chen L.S., Stellrecht C.M., and Gandhi V. RNA-directed agent Cordycepin, induces cell death in multiple myeloma cells. Br. J. Haematol. 140 (2008) 682-691
95. Chen R., Gandhi V., and Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 66 (2006) 10959-10966
96. Quintas-Cardama A., Kantarjian H.M., Wierda W., Ferrajoli A., Chen R., Ravandi F., Plunkett W., and Cortes J. A phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML). ASH Annual Meeting Abstracts 108 (2006) 2174
97. Rosen P.J., Sweeney C.J., Park D.J., Rasmussen E., Shubhakar P., Scripture C., Leitch I., Lu J., Beaupre D.M., and Yee L.K. AMG 102 an HGF/SF antagonist in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors. J. Clin. Oncol. 26 (2008) 3570
98. Bellon S.F., Kaplan-Lefko P., Yang Y., Zhang Y., Moriguchi J., Rex K., Johnson C.W., Rose P.E., Long A.M., O'Connor A.B., Gu Y., Coxon A., Kim T.-S., Tasker A., Burgess T.L., and Dussault I. C-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J. Biol. Chem. 283 (2008) 2675-2683
99. Koblish H.K., Liu X., Hall L., Boer J., He C., Yeleswaram S., Newton R.C., Vaddi K., Yao W., Scherle P.A., and Fridman J.S. Preclinical in vivo characterization of INCB028060, a novel, potent and highly selective c-Met inhibitor. J. Clin. Oncol. 26 (2008) 14561
100. Beaulieu N., Beaulieu C., Dupont I., Nguyen H., Chute I., Gravel S., Durand J., Robert M., Lefebvre S., Lu A., Dubay M., Rahil J., Isakovic L., Claridge S., Saavedra O., Raeppel S., Mannion M., Bernstein N., Zhan L., Gaudette F., Zhou N., Raeppel F., Granger M., Deziel R., Vaisburg A., Wang J., Besterman J., Macleod A., and Maroun R. Preclinical development of MGCD265 a potent orally active c-Met/VEGFR multi-target kinase inhibitor. Proc. Am. Assoc. Cancer Res. 49 (2008) 4838
101. Qi W., Cooke L., Stejskal A., Bearss D., and Mahadevan D. Inhibition of erlotinib resistance on HER-family tyrosine kinases by combination with MP470 a multi-targeted TK inhibitor in prostate and breast cancer. Proc. Am. Assoc. Cancer Res. 49 (2008) 671
102. Trevor K., Combs D., Mahadevan D., Bearss D., and Cranmer L. Activity of the multi-targeted, receptor tyrosine kinase inhibitor MP470 against synovial sarcoma cells. Proc. Am. Assoc. Cancer Res. 49 (2008) 4891
103. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., Yamazaki S., Alton G.R., Mroczkowski B., and Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma,. Mol. Cancer Ther. 6 (2007) 3314-3322
104. Zou H.Y., Li Q., Lee J.H., Arango M.E., Burgess K., Yamazaki S., Parker M., Cui J., Cheng H., McTigue M., Los G., Bender S., and Christensen J.G. PF-04217903, a novel selective c-Met kinase inhibitor with potent antitumor and anti-angiogenic properties in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 49 (2008) 4841
105. Cassinelli G., Lanzi C., Petrangolini G., Tortoreto M., Pratesi G., Cuccuru G., Laccabue D., Supino R., Belluco S., Favini E., Poletti A., and Zunino F. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol. Cancer Ther. 5 (2006) 2388-2397
106. Jessen K., Tang C., Froning K., Felce J., Huser N., Bounaud P., Smith C., Peterman M., Gutierrez A., Leonard S., Aubol B., Gessert S., Sperry S., Tran N., Sahly Y., Holme K., Burley S., Reich S., and Buchanan S. SGX523 a potent and exquisitely selective inhibitor of the HGF receptor tyrosine kinase (MET) inhibits growth of human glioblastoma tumors in a mouse model. Proc. Am. Assoc. Cancer Res. 49 (2008) 4844
107. Salgia R., Hong D.S., Camacho L.H., Ng C.S., Janisch L., Ratain M.J., and Kurzrock R. A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184 a VEGFR and MET kinase inhibitor administered orally to patients (pts) with advanced malignancies. J. Clin. Oncol. 25 (2007) 14031
108. Salgia R., Sherman S., Hong D.S., Ng C.S., Frye J., Janisch L., Ratain M.J., and Kurzrock R. A phase I study of XL184 a RET VEGFR2 and MET kinase inhibitor in patients (pts) with advanced malignancies including pts with medullary thyroid cancer (MTC). J. Clin. Oncol. 26 (2008) 3522
109. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W.C., Yu C.J., Gazdar A., Pass H., Rusch V., Gerald W., Huang S.F., Yang P.C., Miller V., Ladanyi M., Yang C.H., and Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104 (2007) 20932-20937
110. Ross R.W., Stein M., Sarantopoulos J., Eisenberg P., Logan T., Srinivas S., Rosenberg J., and Vaishampayan U. A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J. Clin. Oncol. 25 (2007) 15601
111. Eder J.P., Heath E., Appleman L., Shapiro G., Wang D., Malburg L., Zhu A.x., Leader T., Wolanski A., and LoRusso P. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J. Clin. Oncol. 25 (2007) 3526
112. Anderson K.C. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol. 35 (2007) 155-162
113. Saif M.W., Erlichman C., Dragovich T., Mendelson D., Toft D., Timony G., Burrows F., Padgett C., De Jager R., and Von Hoff D. Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. J. Clin. Oncol. 24 (2006) 10062
114. Patterson J., Palombella V.J., Fritz C., and Normant E. IPI-504 a novel and soluble HSP-90 inhibitor blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother. Pharmacol. 61 (2008) 923-932
115. Sydor J.R., Normant E., Pien C.S., Porter J.R., Ge J., Grenier L., Pak R.H., Ali J.A., Dembski M.S., Hudak J., Patterson J., Penders C., Pink M., Read M.A., Sang J., Woodward C., Zhang Y., Grayzel D.S., Wright J., Barrett J.A., Palombella V.J., Adams J., and Tong J.K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504) an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA 103 (2006) 17408-17413
116. Bryson J.C., Infante J.R., Ramanathan R.K., Jones S.F., Von Hoff D.D., and Bourris III H.A. A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. J. Clin. Oncol. 26 (2008) 14613
117. Garcia A., Rosen L., Cunningham C.C., Nemunaitis J., Li C., Rulewski N., Dovholuk A., Savage R., Chan T., Bukowksi R., and Mekhail T. Phase 1 study of ARQ 197 a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. J. Clin. Oncol. 25 (2007) 3525
118. Jhawer M.P., Kindler H.L., Wainberg Z.A., Hecht J.R., Kerr R.O., Ford J.M., Henderson C., Mueller T., Keer H.N., and Shah M.A. Preliminary activity of XL880 a dual MET/VEGFR2 inhibitor in MET amplified poorly differentiated gastric cancer (PDGC): interim results of a multicenter phase II study. J. Clin. Oncol. 26 (2008) 4572